LitCovid-sentences  

PubMed:33012862 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-70 Sentence denotes The impact of the COVID-19 pandemic response on other health research.
T2 71-311 Sentence denotes While governments have been focusing on the unprecedented disruption to the global economy caused by coronavirus disease 2019 (COVID-19) and the urgent need for COVID-19 research, other health research has become a casualty of the pandemic.
T3 312-528 Sentence denotes Major research operations that are unrelated to COVID-19 have been significantly diminished or suspended entirely because of either COVID-19-related legal restrictions or logistical, staffing or operational concerns.
T4 529-604 Sentence denotes Billions of people globally are currently affected by lockdowns or curfews.
T5 605-788 Sentence denotes Since the timescale of such restrictive measures is unknown and subject to change, many studies are now in limbo and the welfare of tens of thousands of study participants is at risk.
T6 789-936 Sentence denotes These circumstances have introduced complex ethical challenges that merit urgent attention from international sponsors, researchers and regulators.
T7 937-1074 Sentence denotes Certain sponsors and regulators have published guidelines on how the COVID-19-related disruptions to clinical research should be managed.
T8 1075-1258 Sentence denotes Although these guidelines provide a good starting point in navigating the challenges of the evolving pandemic, they only apply to those researchers funded or governed by these bodies.
T9 1259-1358 Sentence denotes Here, we provide guidelines on managing such disruptions that apply beyond these specific settings.
T10 1359-1582 Sentence denotes We highlight some of the effects of the COVID-19 pandemic on other ongoing research projects that are unrelated to COVID-19 and provide practical guidance on how the welfare of affected study participants should be managed.
T11 1583-1794 Sentence denotes We conclude that policy-makers, sponsors, researchers and regulators must adopt a more flexible approach to ensure participant safety, while maintaining data integrity and complying with good clinical practices.